October 26, 2015
Novocure Reports Third Quarter 2015 Operating and Financial Results
FDA approved Optune™ in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015 CE Mark was placed on the second generation Optune system. First patients treated in Europe with the newly designed, smaller, lighter system 468 active patients at quarter… Read More
learn more
October 19, 2015
NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option
October 19, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced the closing today of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public… Read More
learn more
October 16, 2015
Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015
Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients October 16, 2015 05:04 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel… Read More
learn more
October 16, 2015
Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26
October 16, 2015 11:54 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will report financial results for the third quarter of 2015 on Monday, October 26, 2015 after the close… Read More
learn more
October 9, 2015
ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients The EF-14 trial achieved statistically significant extension of both progression-free survival and overall survival in newly diagnosed glioblastoma with a 50% increase… Read More
learn more
October 7, 2015
NovoCure Limited Announces Closing of Initial Public Offering
October 07, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22… Read More
learn more
October 5, 2015
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50% lighter and 50% smaller than the first generation system Second generation Optune, including battery (Photo: Business Wire) Download… Read More
learn more
October 2, 2015
NovoCure Limited Announces Launch of Initial Public Offering
October 01, 2015 09:07 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by… Read More
learn more
